1. The insulin delivery application segment dominated the global needle-free drug delivery devices market in 2014. This is due to the rising prevalence of diabetes and improvement in compliance with insulin regimens.
2. However, going forward, pediatric injections segment is expected to experience the highest growth during the forecast period from 2015 to 2023. This is due to increased public awareness, government initiatives for pediatric vaccination and rising acceptance of novel drug delivery devices for pediatric patients.
3. Zogenix, 3M and Antares Pharma dominated the global needle-free drug delivery devices market in 2014.
4. The largest share of the needle-free drug delivery devices market in 2014 was the jet injectors segment. The report cites increasing amounts of needle stick injuries and possible transmission of blood borne pathogens by needle as the main drivers of the segment.
More articles on supply chain:
Medicare’s proposed drug pricing plan raises bipartisan concerns
Northwestern researchers: FDA faces room for improvement in regulation of female health devices
Physicians approve stroke prevention device for FDA approval after 13 years of research
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
